Nivolumab plus relatlimab for melanoma in the brain
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 study tests whether nivolumab plus relatlimab can shrink or control melanoma that has spread to the brain. It may help by boosting the immune system to attack the cancer, including melanoma in brain areas that can’t be treated with prior focused radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have melanoma confirmed by pathology and at least one measurable brain tumor spot on MRI (between 0.5 cm and 3 cm).
- The brain tumor spot you’re counting has not been treated with focused radiation (SRS) before.
- You must be able to provide tumor tissue for PD-L1 testing (or agree to a biopsy during screening), unless tissue is not feasible.
- You need to be well enough for treatment (ECOG 0–1) and have steroid meds situation that fits the rules (no steroid treatment in the last 5 days for brain-symptom prevention, except normal replacement doses).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial tests a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) for people with melanoma that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
This trial studies whether giving the immunotherapy drug nivolumab together with targeted brain radiation (not whole-brain radiation) helps people with melanoma that has spread to the brain. It aims to improve brain control while keeping side effects manageable.
This study tests a combination of two immunotherapy drugs (nivolumab and relatlimab) for people with advanced melanoma that cannot be removed by surgery or has spread. These drugs help your immune system fight the cancer more effectively.
This Phase 2 study tests whether a 3-drug plan (encorafenib + binimetinib + nivolumab) works better than ipilimumab + nivolumab for melanoma that has spread to the brain. If you qualify, you’ll get either treatment and have frequent brain scans to track how well it controls the tumors.
This Phase 2 study tests crizanlizumab alone or with nivolumab to treat people with certain brain tumors that have spread to the brain (melanoma) or glioblastoma. The goal is to see whether this approach can control the disease and improve outcomes.
Hear when a new Melanoma (Skin) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.